In addition to reporting that DLC1 protein is a new critical substrate for cytoplasmic EZH2, this study provides a rational approach for combination molecular targeted agent cancer treatment by non-genetically reactivating a tumor suppressor protein, leading to potent antitumor activity. Here, EZH2 is linked to cancer.